当前位置: 首页 >> 检索结果
41. Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
作者: Albert Wiegman.;Amy L Peterson.;Robert A Hegele.;Eric Bruckert.;Anja Schweizer.;Anastasia Lesogor.;Yibo Wang.;Joep Defesche.
来源: Circulation. 2025年151卷25期1758-1766页
Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease. Early treatment initiation is crucial for cardiovascular risk reduction; however, many patients do not reach LDL-C treatment goals. Inclisiran, a small interfering RNA targeting hepatic PCSK9 (proprotein convertase subtilisin/kexin type 9), is effective and well tolerated in adult patients with hyperlipidemia; however, it has not yet been studied in pediatric patients.
42. Sex-Related Prognosis of VA-ECMO-Treated Cardiogenic Shock: A Post Hoc Analysis of the HYPO-ECMO Trial.
作者: Guillaume Baudry.;Nicolas Girerd.;Kevin Duarte.;Luca Monzo.;Clément Delmas.;Harriette G C Van Spall.;Antoine Kimmoun.;Bruno Levy.
来源: Circ Heart Fail. 2025年18卷8期e012702页
The sex-related prognosis of patients with cardiogenic shock undergoing venoarterial extracorporeal membrane oxygenation remains unclear. Our analyses aim to assess sex-specific outcomes in patients with cardiogenic shock receiving venoarterial extracorporeal membrane oxygenation and explore whether the effect of moderate hypothermia on clinical outcomes was modified by sex.
43. Periaortic Fat Attenuation on Nongated Noncontrast Chest CT Images to Assess Changes in Arterial Inflammation: Impact of Atorvastatin.
作者: Guillaume Goudot.;Shady Abohashem.;Michael T Osborne.;Wesam Aldosoky.;Taha Z Ahmad.;Michael T Lu.;Borek Foldyna.;Ahmed Tawakol.
来源: Circ Cardiovasc Imaging. 2025年18卷7期e017248页
Imaging markers of atherosclerotic inflammation are needed to enhance cardiovascular risk assessment and evaluate the impact of therapies. We sought to test the hypothesis that treatments impacting arterial inflammation can be evaluated using a simplified measure of periaortic fat attenuation (FA) assessed on noncontrast, nongated computed tomography of the descending thoracic aorta.
44. Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock.
作者: Hoong Sern Lim.;Dagmar Vondrakova.;Jan Belohlavek.;Richard Rokyta.;Petr Ostadal.
来源: Circ Heart Fail. 2025年18卷7期e012847页
Hemodynamic response to escalation of vasoactive drugs has not been well-characterized in patients with cardiogenic shock (CS). We tested the hypothesis that lower diastolic perfusion pressure (DPP=diastolic blood pressure-right atrial pressure) was associated with more limited hemodynamic response to uptitration of vasoactive drugs and with possible benefit from early mechanical circulatory support in patients with CS.
45. Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial.
作者: Tetsuya Ishikawa.;Masahiro Natsuaki.;Hirotoshi Watanabe.;Takeshi Morimoto.;Ko Yamamoto.;Yuki Obayashi.;Ryusuke Nishikawa.;Kenji Ando.;Satoru Suwa.;Tsuyoshi Isawa.;Hiroyuki Takenaka.;Ruka Yoshida.;Hiroshi Suzuki.;Gaku Nakazawa.;Takanori Kusuyama.;Itsuro Morishima.;Syun Hojo.;Joshi Tsutsumi.;Hirosada Yamamoto.;Hiroshi Ueda.;Koh Ono.;Takeshi Kimura.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015197页
The effects of the aspirin-free strategy on bleeding and cardiovascular events were unknown in patients with high bleeding risk (HBR), with or without acute coronary syndrome (ACS), undergoing percutaneous coronary intervention.
46. Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial.
作者: Sachin S Goel.;Ashrith Guha.;JoAnn Lindenfeld.;William T Abraham.;Saibal Kar.;Samir R Kapadia.;Stephen H Little.;D Scott Lim.;Michael J Reardon.;Neal S Kleiman.;Janani Aiyer.;Lak N Kotinkaduwa.;Michael J Mack.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2025年18卷7期e015192页
The clinical significance of elevated baseline natriuretic peptide level and prior heart failure hospitalization (HFH) within the prior year in mitral transcatheter edge-to-edge repair outcomes is unclear. This analysis examined the impact of BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal pro-B-type natriuretic peptide) and prior HFH on outcomes in patients with severe secondary mitral regurgitation.
47. Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
作者: Constantin-Cristian Topriceanu.;Christoffer Rasmus Vissing.;Anna Axelsson Raja.;Sharlene M Day.;Mark W Russell.;Kenneth Zahka.;Alexandre C Pereira.;Steven D Colan.;Anne M Murphy.;Charles Canter.;Richard G Bach.;Matthew T Wheeler.;Joseph W Rossano.;Anjali T Owens.;Luisa Mestroni.;Matthew R G Taylor.;James C Moon.;Gabriella Captur.;Amit R Patel.;Ivan Wilmot.;Jonathan H Soslow.;Jason R Becker.;Christine E Seidman.;Neal K Lakdawala.;Henning Bundgaard.;Usman A Tahir.;Carolyn Y Ho.
来源: Circ Heart Fail. 2025年18卷6期e012393页
In hypertrophic cardiomyopathy (HCM), the mechanisms through which pathogenic sarcomere variants (G+) lead to left ventricular hypertrophy (LVH) are not understood.
48. Transapical Beating-Heart Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy: Lessons Learned After the Learning Curve Period.
作者: Jing Fang.;Yue Chen.;Yani Liu.;Rui Li.;Ying Zhu.;Wei Zhou.;Lin Cheng.;Qunhui Wang.;Juan Shi.;Yupeng Wei.;Yilei Ma.;Eduard Quintana.;Juan B Grau.;Song Wan.;Xiang Wei.
来源: Circ Cardiovasc Interv. 2025年18卷5期e015044页
The transapical beating-heart septal myectomy (TA-BSM) procedure was developed to enhance efficiency and reduce surgical trauma compared with conventional septal myectomy in treating obstructive hypertrophic cardiomyopathy. The current study aimed to delineate a refined TA-BSM surgical technique and summarize the midterm outcomes of the cohort immediately after the learning curve period.
49. Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits.
作者: Daniel T Y Ang.;Damien G Collison.;Ross J McGeoch.;David Carrick.;Robert A Sykes.;Conor Bradley.;Anna L Kamdar.;Andy Jong.;Richard A Brogan.;David A MacDougall.;Peter J McCartney.;J Paul Rocchiccioli.;Andrew P Apps.;C Aengus Murphy.;Keith E Robertson.;Aadil Shaukat.;Angie Ghattas.;Francis R Joshi.;Arvind Sood.;Richard I S Good.;Brian O'Rourke.;Hany Eteiba.;M Mitchell Lindsay.;Alex McConnachie.;Colin Berry.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015058页
Intravenous adenosine induces stable myocardial hyperemia for coronary microvascular function testing. Iodinated radiographic contrast media induce transient, submaximal hyperemia. We assessed the feasibility, diagnostic value, and potential cost-effectiveness of contrast-derived indices of microvascular function.
50. COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.
作者: Veronika Sochorová.;Veronika Kunštátová.;Pavel Osmančík.;František Duška.;Dalibor Heřman.;Petr Waldauf.;Lukáš Povišer.;Jakub Karch.;Lucie Znojilová.;Věra Filipcová.;Jana Hozmanová.;Jana Veselá.;Marek Hozman.
来源: Circulation. 2025年152卷3期150-159页
Deep analgosedation (DAS) or general anesthesia is mandatory for pulsed-field ablation of atrial fibrillation. In contrast to DAS, general anesthesia (conventional or total intravenous anesthesia [TIVA]) requires airway management. To find the optimal sedation regimen, this study compared ketamine-remimazolam DAS and propofol-opioid TIVA with propofol-opioid DAS, focusing on sedation-related adverse events.
51. Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial.
作者: Louise R A Olde Nordkamp.;Jolien A de Veld.;Abdul Ghani.;Jürgen Kuschyk.;Hendrik Bonnemeier.;Kerstin Bode.;Lucas V A Boersma.;Anouk de Weger.;Jonas S S G de Jong.;Ward P J Jansen.;Marco Alings.;Nick Bijsterveld.;Mikhael F El-Chami.;Rypko J Beukema.;Kevin Vernooy.;Berit T Philbert.;Petr Neuzil.;Peter Nordbeck.;Jurren M van Opstal.;Cornelis P Allaart.;David J Wright.;Michael Knaut.;Timothy R Betts.;Zachary I Whinnett.;Pier D Lambiase.;Joris R de Groot.;Alexandru B Chicos.;Dimitry Nemirovksy.;Stefan Kääb.;Suneet Mittal.;Alida E Borger van der Burg.;Leonard A Dijkshoorn.;Shari Pepplinkhuizen.;Willeke van der Stuijt.;Jose M Dizon.;Marc A Miller.;Elijah R Behr.;Martin C Burke.;Kirsten M Kooiman.;Anne-Floor B E Quast.;Tom F Brouwer.;Arthur A M Wilde.;Lonneke Smeding.;Reinoud E Knops.; .
来源: Circulation. 2025年152卷3期172-182页
The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) investigated the efficacy and safety of the subcutaneous implantable cardioverter defibrillator (S-ICD) compared with a transvenous ICD (TV-ICD) and showed noninferiority of the S-ICD with regard to the composite end point of device-related complications and inappropriate shocks after 49.1 months. Complications associated with transvenous leads are expected to occur after longer follow-up. The PRAETORIAN-XL trial aims to investigate whether the S-ICD is superior to the TV-ICD with respect to device-related complications at 8-year follow-up.
52. Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2.
作者: Vivek Y Reddy.;Edward P Gerstenfeld.;Boris Schmidt.;Jason G Andrade.;Devi Nair.;Andrea Natale.;Walid Saliba.;Philipp Sommer.;Andreas Metzner.;Atul Verma.;Troy Hounshell.;Anish Amin.;Philip Gentlesk.;Stanislav Weiner.;Frank A Cuoco.;Jamie Kim.;Mohit K Turagam.;Gery Tomassoni.;Chinmay Patel.;Ziad Issa.;Michael Shehata.;Allison M Anderson.;Thomas J Stoltz.;Jonathan D Raybuck.;Torri Schwartz.;Brad S Sutton.;Moussa Mansour.; .
来源: Circulation. 2025年152卷1期27-40页
There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter.
53. Impact of Acute Antioxidant and Tetrahydrobiopterin (BH4) Administration on Locomotor Muscle Microvascular Function in Patients With Heart Failure.
作者: Stephen M Ratchford.;Heather L Clifton.;Jayson R Gifford.;D Taylor LaSalle.;Taylor S Thurston.;Kanokwan Bunsawat.;Jeremy K Alpenglow.;Josephine B Wright.;Markus Amann.;John J Ryan.;D Walter Wray.
来源: Circ Heart Fail. 2025年18卷6期e012446页
Peripheral microvascular dysfunction is a hallmark feature of both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) pathophysiology, due partly to impairments in nitric oxide signaling secondary to tetrahydrobiopterin (BH4) deficiency and oxidative stress.
54. Adenosine Contrast Correlations in Evaluating Revascularization: The (ACCELERATION) Study.
作者: Rajesh V Swaminathan.;Guillaume Marquis-Gravel.;Laurie-Anne Boivin-Proulx.;Daniel K Benjamin.;Aruna Rikhi.;Ganesh Raveendran.;Jeff W Chambers.;Arnold H Seto.;Jayant Bagai.;Roseann White.;Jorge Antonio Gutierrez.;Thomas J Povsic.;Sunil V Rao.;Mitchell W Krucoff.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015240页
Injection of contrast media for rapid measurement of contrast fractional flow reserve (cFFR) obviates the side effects and time requirements of adenosine fractional flow reserve (aFFR) and improves diagnostic performance relative to nonhyperemic pressure ratios. However, studies of cFFR have had variable delivery of contrast. We evaluated the diagnostic performance of cFFR using an automated contrast injector with a standardized volume and rate of delivery of contrast to the reference standard aFFR.
55. Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
作者: Jesper Kjaergaard.;Christian Holdflod Møller.;Sebastian Wiberg.;Astrid Duus Mikkelsen.;Hasse Møller-Sørensen.;Hanne Berg Ravn.;Jesper Ravn.;Peter Skov Olsen.;Dan E Høfsten.;Søren Boesgaard.;Lars Køber.;Jens Christian Nilsson.;Christian Hassager.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014961页
GLP-1 (glucagon-like peptide-1) agonists have been proven beneficial in reducing the risk of and injury associated with several cardiovascular diseases. The efficacy in cardiopulmonary bypass-assisted cardiac surgery is unknown. This trial aimed to investigate the efficacy of an infusion of the GLP-1 agonist exenatide during and after open-heart surgery in reducing the risk of death and major organ failure.
56. Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications.
作者: Pavan Reddy.;Fernando J Rodriguez-Weisson.;Giorgio A Medranda.;Ilan Merdler.;Matteo Cellamare.;Paul Gordon.;Afshin Ehsan.;Puja Parikh.;Thomas Bilfinger.;Maurice Buchbinder.;David Roberts.;Nicholas Hanna.;Itsik Ben-Dor.;Lowell F Satler.;Hector M Garcia-Garcia.;Federico M Asch.;Gaby Weissman.;Anita Sadeghpour.;Christian C Schults.;Ron Waksman.;Toby Rogers.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014802页
Patients with bicuspid aortic stenosis who receive transcatheter aortic valve replacement (TAVR) may require subsequent valve interventions in their lifetime; however, the feasibility of redo-TAVR in this population is uncertain. We aimed to assess redo-TAVR feasibility in bicuspid patients and develop a predictive virtual valve planning algorithm.
57. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
作者: Andre Zimerman.;Ana Laura F Kunzler.;Brittany N Weber.;Xinhui Ran.;Sabina A Murphy.;Huei Wang.;Narimon Honarpour.;Anthony C Keech.;Peter S Sever.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2025年151卷20期1467-1476页
Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.
58. Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure.
作者: Michael R Zile.;William T Abraham.;Lynne W Stevenson.;Maria Rosa Costanzo.;Christiane E Angermann.;Mandeep R Mehra.;Akshay S Desai.;Anique Ducharme.;Nessa Johnson.;John Henderson.;JoAnn Lindenfeld.
来源: Circ Heart Fail. 2025年18卷6期e012754页
Hemodynamically guided management of patients with chronic heart failure (HF), using a remote, ambulatory pulmonary artery (PA) pressure monitor, has been shown to reduce mortality and morbidity. These improved outcomes were associated with a reduction in PA pressure. However, several pivotal questions remain unanswered: do systolic, diastolic, or mean PA pressures each predict all-cause mortality? Do PA pressures predict mortality across the ejection fraction (EF) spectrum? Do increases or decreases in PA pressure over time predict increases or decreases in mortality?
59. Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial.
作者: Gaoqiang Xie.;Anushka Patel.;Xin Du.;Yihong Sun.;Xian Li.;Tao Wu.;Zhixin Hao.;Runlin Gao.;Yangfeng Wu.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011441页
Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge.
60. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
|